ASTRO participates in FDA’s meeting to discuss highest level of safety for radiation therapy patients Society users on improving tools usability present, dependence on reporting systemThe American Culture for Radiation Oncology continued to advance it is Target Safely initiative by participating in the Food and Medication Administration’s public meeting on Device Improvements to Reduce the Number of Under-Doses, Over-Doses, and Misaligned Exposures from Therapeutic Radiation on June 9 and 10. ASTRO commends the FDA on keeping this meeting to recognize current issues and additional develop data, which will help inform the FDA’s actions to ensure the highest level of basic safety for radiation therapy patients. Related StoriesUM SOM researchers to initiate first clinical trial of GammaPod program in sufferers with early-stage breast cancerUniversity of Maryland develops GammaPod system to take care of early-stage breast cancerStudy could help mitigate ramifications of ageing on blood stem cells, promote brand-new therapies for anaemiaNumerous experts from the radiation therapy community, including those from scientific practice, academia and these devices industry, gathered to handle protection in radiation therapy.Other St. Jude researchers who’ve received the Pediatric Oncology Award include Evans; Mary Relling, Pharm.D., Pharmaceutical Sciences seat; Larry Kun, M.D., medical Radiological and director Sciences chair; and Ching-Hon Pui, M.D., Oncology chair.. Accuray receives shareholders authorization to acquire TomoTherapy Accuray Integrated , a worldwide leader in neuro-scientific radiosurgery, announced today that TomoTherapy shareholders have approved the proposed acquisition of TomoTherapy Integrated by Accuray. More than 98 % of votes cast and 79 % of shares excellent were voted and only the transaction. The ongoing companies anticipate the closing of the transaction will occur within one to two business days, assuming all other customary closing circumstances are met.